A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92037-0845, United States
Los Angeles, California 90033, United States
Los Angeles, California 90095, United States
Ann Arbor, Michigan 48109-2800, United States
St Louis, Missouri 63110, United States
St Louis, Missouri 63110, United States
Hackensack, New Jersey 07601, United States
Greenfield Park, Quebec J4V 2H1, Canada
Rome, 00161, Italy
Gdansk, Pomeranian Voivodeship 80-952, Poland
Lodz, 93-513, Poland
Wroclaw, 53-439, Poland